MX2007003904A - Pentraxina larga ptx3 desglicosilada y desialidada. - Google Patents

Pentraxina larga ptx3 desglicosilada y desialidada.

Info

Publication number
MX2007003904A
MX2007003904A MX2007003904A MX2007003904A MX2007003904A MX 2007003904 A MX2007003904 A MX 2007003904A MX 2007003904 A MX2007003904 A MX 2007003904A MX 2007003904 A MX2007003904 A MX 2007003904A MX 2007003904 A MX2007003904 A MX 2007003904A
Authority
MX
Mexico
Prior art keywords
long pentraxin
deglycosylated
pentraxin ptx3
desialidated
preparation
Prior art date
Application number
MX2007003904A
Other languages
English (en)
Inventor
Rita De Santis
Giovanni Salvatori
Paolo Carminati
Antonio Inforzato
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2007003904A publication Critical patent/MX2007003904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se describe pentraxina larga PTX3 desglicosilada y pentraxina larga PTX3 desialidada, asi como procedimientos para su preparacion, composiciones farmacologicas que las contienen, y su uso para la preparacion de un medicamento para el tratamiento de enfermedades en donde se indica el uso de pentraxina larga PTX, particularmente enfermedades infecciosas e inflamatorias, y trastornos de fertilidad femenina. Estas proteinas estan dotadas de actividad terapeutica superior a aquella de La pentraxina glicosilada.
MX2007003904A 2004-10-08 2005-09-28 Pentraxina larga ptx3 desglicosilada y desialidada. MX2007003904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000489A ITRM20040489A1 (it) 2004-10-08 2004-10-08 Pentraxina lunga ptx3 deglicosilata o desialidata.
PCT/EP2005/054860 WO2006037744A1 (en) 2004-10-08 2005-09-28 Deglycosylated and desialidated long pentraxin ptx3

Publications (1)

Publication Number Publication Date
MX2007003904A true MX2007003904A (es) 2007-06-07

Family

ID=35708940

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003904A MX2007003904A (es) 2004-10-08 2005-09-28 Pentraxina larga ptx3 desglicosilada y desialidada.

Country Status (24)

Country Link
US (2) US7683032B2 (es)
EP (1) EP1797120B1 (es)
JP (1) JP5014999B2 (es)
KR (1) KR101426783B1 (es)
CN (1) CN101035805B (es)
AR (1) AR051053A1 (es)
AT (1) ATE509950T1 (es)
AU (1) AU2005291280B2 (es)
BR (1) BRPI0516554A (es)
CA (1) CA2580426C (es)
CY (1) CY1112440T1 (es)
DK (1) DK1797120T3 (es)
ES (1) ES2366370T3 (es)
HK (1) HK1110870A1 (es)
HR (1) HRP20110595T1 (es)
IT (1) ITRM20040489A1 (es)
ME (1) ME01947B (es)
MX (1) MX2007003904A (es)
PL (1) PL1797120T3 (es)
PT (1) PT1797120E (es)
RS (1) RS51900B (es)
SI (1) SI1797120T1 (es)
TW (1) TWI380995B (es)
WO (1) WO2006037744A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
WO2009095403A1 (en) * 2008-01-29 2009-08-06 Tecnogen S.P.A. Expression system and uses thereof for the production of human long pentraxin 3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
WO2003011902A1 (en) 2001-07-27 2003-02-13 Kenton S.R.L. Identification of specific tumour antigens by selection of cdna libraries with sera
DK1411971T3 (da) * 2001-08-03 2006-08-07 Sigma Tau Ind Farmaceuti Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.

Also Published As

Publication number Publication date
TW200628488A (en) 2006-08-16
PT1797120E (pt) 2011-08-23
BRPI0516554A (pt) 2008-09-09
ES2366370T3 (es) 2011-10-19
KR101426783B1 (ko) 2014-08-05
AR051053A1 (es) 2006-12-13
US20100209442A1 (en) 2010-08-19
EP1797120A1 (en) 2007-06-20
RS51900B (en) 2012-02-29
CN101035805B (zh) 2011-04-06
JP5014999B2 (ja) 2012-08-29
KR20070083769A (ko) 2007-08-24
US20070249021A1 (en) 2007-10-25
US7833981B2 (en) 2010-11-16
WO2006037744A1 (en) 2006-04-13
EP1797120B1 (en) 2011-05-18
CN101035805A (zh) 2007-09-12
HRP20110595T1 (hr) 2011-09-30
PL1797120T3 (pl) 2011-12-30
AU2005291280B2 (en) 2011-10-20
ME01947B (me) 2012-02-29
AU2005291280A1 (en) 2006-04-13
JP2008515846A (ja) 2008-05-15
DK1797120T3 (da) 2011-09-05
CA2580426A1 (en) 2006-04-13
SI1797120T1 (sl) 2011-12-30
HK1110870A1 (en) 2008-07-25
ATE509950T1 (de) 2011-06-15
CA2580426C (en) 2015-01-13
TWI380995B (zh) 2013-01-01
US7683032B2 (en) 2010-03-23
ITRM20040489A1 (it) 2005-01-08
CY1112440T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
WO2007136518A3 (en) Treatment of autoimmune disorders
PH12020500028A1 (en) Crystalline forms of a bruton`s tyrosine kinase inhibitor
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
SG10201809947UA (en) Use of prg4 as an anti-inflammatory agent
NZ709704A (en) Protein formulations and methods of making same
CL2008002138A1 (es) Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células.
DK1709161T3 (da) Humane terapeutiske celler, som udskiller nervevækstfaktor
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
TW200801031A (en) Steroid nitrooxyderivatives
YU30002A (sh) Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina
MX2007003904A (es) Pentraxina larga ptx3 desglicosilada y desialidada.
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
WO2000040273A8 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
CN204233403U (zh) 一种多功能汽车按摩垫
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
WO2006110577A3 (en) Use of fril proteins for reducing the production of pro-inflammatory cytokines
WO2021050564A3 (en) Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders
EP3903789A4 (en) THERAPEUTIC MEDICINE FOR A DISEASE ACCOMPANIED BY DISORDERS IN CELLS OF THE RETINAL SYSTEM OR RETINA TISSUE
Han et al. Low-dose decitabine restores immune tolerance in ITP by modulating regulatory T cells
CN203251964U (zh) 一种女性提臀塑裤
CN204379996U (zh) 一种近红外线座凳

Legal Events

Date Code Title Description
FG Grant or registration